UPDATE: Wedbush Downgrades Cubist Pharmaceuticals Following Slight Q3:13 Results Miss
In a report published Thursday, Wedbush analyst Gregory R. Wade downgraded the rating on Cubist Pharmaceuticals (NASDAQ: CBST) from Outperform to Neutral, but reiterated the $65.00 price target.
In the report, Wedbush noted, “Cubist reported Q3:13 financials with US CUBICIN revenues of $229.9M, slightly lower than our estimated $238M and only slightly ahead of Q2's $227M. Tightened FY:13 CUBICIN guidance of $885-$900M suggests Q4:13 sales in the range of $225.9-240.9M. CBST reiterated its guidance that the Phase III ceftolozane/tazobactam data in the cUTI setting would be announced later in November and cIAI in late December. An NDA filing is expected about 6 months following potentially positive cIAI data.”
Cubist Pharmaceuticals closed on Wednesday at $63.25.
Latest Ratings for CBST
|Dec 2014||RBC Capital||Downgrades||Outperform||Sector Perform|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.